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Perceived Ability to Treat Opioid Use Disorder in West Virginia
Abstract
Introduction: Medication-assisted treatment (MAT) is an evidence-based therapy for opioid use disorder
(OUD) that has not been fully implemented in rural areas due to patient, provider, and logistical barriers.
Limited information is available on provider perceptions of barriers to MAT in rural Central Appalachia
which has very high rates of OUD compared to the rest the United States.
Purpose: Determine perceived barriers for potential prescribers to using MAT, including buprenorphine, as
part of treatment for OUD in West Virginia.
Methods: A 30-question, anonymous survey was sent to physicians, physician assistants and advanced
practice registered nurses using an online link. Link was distributed through the WV Medicaid provider list,
professional association and institutional contact lists, and social media. Comparisons were made by
provider waivered or non-waivered status.
Results: Overall, 84% of waivered providers (n = 77) and only 8% of non-waivered providers (n = 341)
indicated ever prescribing a form of MAT for OUD; 73% percent of waivered providers were currently
prescribing MAT and accepting new patients with OUD. Only 4% of non-waivered providers were currently
prescribing MAT and 21% were currently accepting new patients with OUD. Lack of available mental
health and psychosocial support services and concerns about diversion or misuse of medication were the
top perceived barriers to implementing MAT programs.
Implications: Implementing strategies to improve access to behavioral health care including telehealth
and apps, provider training and addressing stigma around OUD treatment were identified as priorities that
would help increase providers’ willingness to prescribe medications for OUD treatment.
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INTRODUCTION

H

igher rates of occupational injuries and chronic pain coupled with
declining economic opportunities and a flood of prescription opioids
have fueled rising rates of opioid misuse, resulting in rates of opioid use
disorder (OUD) in Central Appalachia that are much higher than other parts of
the U.S.1 West Virginia currently leads the nation in per capita opioid overdose
deaths. It’s rate of drug overdose deaths in 2016 (52 per 100,000) was more than
250% higher than the national rate (19.8 per 100,000).2 Medication-assisted
treatment (MAT) is an effective, evidence-based therapy for OUD that can reduce
cravings and promote relapse prevention that has been associated with a
reduction in opioid overdose deaths.3 A recent systematic review with metaanalysis observed a 76% reduction in mortality risk among individuals with
opioid use disorder while receiving MAT from 16 studies (pooled crude mortality
rate [CMR], 0.24 [95% CI, 0.20–0.28]). Individuals not receiving MAT were eight
times more likely to die from overdose (RR 8.10, 95% CI, 4.48–14.66) compared
to patients receiving treatment.4 Despite this demonstrated efficacy, barriers
remain to implementation in rural practices. Commonly reported barriers by
rural providers include lack of knowledge about MAT; lack of specialty backup;
concerns over drug diversion if medications are prescribed; insufficient provider
staff time, reimbursement, resource availability including behavioral health, and
stigma.5,6
Efforts are currently underway in West Virginia (WV) to expand buprenorphine
treatment via a hub-and-spoke model.7 Under a hub-and-spoke model, smaller
hospitals and clinics (i.e., spokes) are connected with larger organizations with
specialty care (i.e., hubs) to increase local provider education and facilitate local
treatment capacity and transfers to specialty care when indicated.8 This model
has been found to be particularly helpful in the rural setting where declining
employment opportunities and other resource strains have led to small hospital
and clinic closures.8 In particular, the hub and spoke system may overcome the
previously observed MAT implementation barriers in rural settings, especially
provider lack of knowledge and specialty backup.8 However, there is no
previously published information regarding perceived MAT prescribing barriers
reported by providers in WV, which has the highest opioid overdose death rate
in the nation.9 A cross-sectional survey of WV providers was conducted to
elucidate perceived barriers to implementing MAT programs that may inform
policy and other structural interventions to promote diffusion of this life-saving,
evidence-based treatment (see Additional Files).

Published by the University of Kentucky, 2021

34

Journal of Appalachian Health, Vol. 3 [2021], Iss. 2, Art. 4

METHODS
Participants and Procedures
A cross-sectional study using total population sampling was conducted using an
online survey link and recruitment script. The survey link embedded within the
recruitment script was sent to the email on file to a total of 20,762 individuals
on the WV Medicaid provider list at the time of the study. This list included
physicians (N=15,667), physician assistants (N=1833) and advanced practice
registered nurses (N=3262). Additional requests to complete the survey using the
link sent to the e-mail address on file with WV Medicaid were through
professional association and institutional contact lists, and social media.
Participants completed an anonymous 30-item survey adapted from a national
study6 concerning the ability to use MAT as part of OUD treatment, hosted
through Qualtrics (Provo UT). Data were collected between April 2019 and July
2019. MAT was defined as buprenorphine, methadone, naloxone, and injectable
naltrexone except where exclusively stated otherwise in the survey. Forced
choice, ranking, and open-ended questions were used. The West Virginia
University Institutional Review Board acknowledged the study as exempt.
Data Analysis
Results are presented using descriptive statistics. Data regarding barriers to
providing MAT as part of OUD treatment were collected on an ordinal scale and
independent samples Mann-Whitney U tests (α=0.05) with Bonferroni
corrections to account for multiple comparisons were used to evaluate
differences in mean ranks as a function of provider waiver status using SPSS
v26. Note that physicians, nurse practitioners, and physician assistants must
obtain a waiver from the Drug Enforcement Administration to allow them to
prescribe buprenorphine for the treatment of opioid use disorder.10 Qualitative
analysis of the responses to open-ended questions were reviewed by each
member of the research team and consensus was reached on major themes
emerging from the data.

RESULTS
The survey received 780 clicks and the final sample size, based on those who
accessed the survey, was 431 respondents who completed at least one question
on the survey (55.3%). A total of 303 respondents completed the entire survey
(38.8%). Respondents’ age ranged from 25 to 77 years (mean=49 years, n=194).
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Sample characteristics are summarized in Table 1. The number of responses to
each individual question are provided in Tables 1 and 2.

Table 1. Sample Characteristics

ZIP Code
West Virginia ZIP code
Gender
Female
Male
Provided clinical practice type
Rural health clinic
Hospital-sponsored clinic
Community health clinic or federally
qualified health center
Private practice
Veterans Affairs facility
Behavioral health facility
Emergency department
Inpatient hospital
Substance use treatment facility
Other type of facility
Type of Reimbursement for MAT (select
all that apply)
Private insurance
Medicare
Medicaid
Self-pay
WV Public Employees Insurance Agency

N of respondents
for each
question type
259
239
264
144
120
317
31
60
42

% of respondents
for question

53
4
24
25
25
12
41
203

17
1
8
8
8
4
13

149
147
154
148
139

73
72
76
73
69

92
55
46
10.
19
13

Major themes that emerged from open comments on reasons providers chose to
offer MAT in their clinics they listed better outcomes, number of patients
presenting with the problem, lack of providers for pregnant women, patient
request, effectiveness, and starting practice in a clinic already providing MAT.
Open comments indicated that stigma towards individuals with an OUD and
providers who use medication to treat OUD, administrative burden, diversion,
and lack of training/comfort in prescribing were perceived barriers to
implementing MAT programs. Table 2 illustrates capacity and willingness to
prescribe MAT as part of OUD treatment. Providers were most likely to accept
patients on their current panel for MAT (n=85), followed by patients in their
community not in their practice (n=75), patients of other clinicians in their clinic
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(n=59) and patients outside their community (n=51). Two questions adapted from
published literature11 that assessed implicit bias related to treatment of
substance use disorder were also included in the survey (see Supplemental
Materials) as an additional measure of stigma towards individuals that misuse
substances. Respondents reacted more positively to increasing general mental
health funding (61%; n=115) versus specific funding for OUD treatment (45%;
n=397).
Table 2. Capacity and Willingness to Prescribe MAT
Survey Item

Have you taken the mandatory training to
allow you to apply for a DEA waiver to
prescribe buprenorphine?
If yes to completing the training, have you
received a DEA waiver to allow you to
prescribe buprenorphine?
Have you ever prescribed any form of MAT
(buprenorphine, methadone, or
naltrexone/Vivitrol) for treatment of OUD?
Do you currently prescribe MAT for
treatment of OUD as part of your practice?
If no to having a waiver: If free training is
made available and you were compensated
for your time, would you be willing to obtain
your DEA waiver to prescribe
buprenorphine?
Are you currently accepting new patients
with OUD?
Do you feel reimbursement should be
increased for treatment of OUD?
Do you feel reimbursement should be
increased for treating mental illness?

Yes

Total # of
responses

n

428

No

98

%
Total
23

n
330

%
Total
77

102

77

75

25

25

431

95

22

336

78

430

69

16

361

84

327

183

56

144

44

330

106

32

224

68

397

179

45

218

55

115

70

61

45

39

Mean rank was higher for non-waivered providers compared to those with
waivers on all perceived barriers to incorporating MAT into treatment of OUD
except financial/reimbursement concerns. Lack of available mental health or
psychosocial support services and concerns about diversion or misuse of
medication were ranked as first and second for all providers, in opposite order
for non-waivered and waivered providers, respectively. Statistically significant
differences in mean ranks of perceived barriers dependent upon waiver status
included: lack of available mental health or psychosocial support services,

https://uknowledge.uky.edu/jah/vol3/iss2/4
DOI: https://doi.org/10.13023/jah.0302.04

37

Sheppard et al.: Opioid Use Disorder in West Virginia

concerns about diversion or misuse of medication, concerns about legal liability,
lack of specialty backup for complex problems, concerns about attracting drug
users to practice, outside scope of practice, lack of confidence in ability to
manage patients with OUD, and lack of patient need (Table 3).
Table 3. Mean Ranking of Barriers to Implementing MAT
WAIVERED
N = 77

n
70

Rank
2

Mean
2.51

70

1

2.52

69

5

2.29

69

6

2.24

68
70

3
11

2.42
1.84

70

13

1.45

70

14

1.41

70

8

2.01

70

4

2.39

70

10

1.88

69

12

1.72

70

7

2.07

Likert Scale:
1–Not a concern
2–Minor concern
3–Serious concern
4–Very serious concern
Barrier
Lack of available mental
health or psychosocial
support services
Concerns about diversion
or misuse of medication

NOT WAIVERED

Mann-Whitney

N = 319*

Bonferroni Correction
α=0.003

n
252

Rank
1

Mean
3.16

N
322

U
6100

p
<0.0001

253

2

2.96

323

6782

0.002

Concerns about legal
liability
Lack of specialty backup
for complex problems

254

3

2.82

323

6437

0.0004

253

4

2.71

322

6467

0.0001

Time constraints
Concerns about
attracting drug users to
your practice
Outside my scope of
practice
Lack of confidence in my
ability to manage
patients with OUD
Concerns with DEA
intrusion on your
practice
Financial/reimbursement
concerns
Resistance from practice
partners
Resistance from practice
administration

254
253

6
7

2.54
2.51

322
323

8146
6112

0.455
<0.0001

258

5

2.60

328

4042

<0.0001

254

8

2.38

324

4313

<0.0001

251

9

2.18

321

8338

0.495

253

12

1.99

323

10713

0.005

253

10

2.06

323

8232

0.342

250

11

2.03

319

7557

0.094

Resistance from
253
13
1.93 323 9705
0.193
community
50
9
1.98 Other
126
14
1.86 176 3181
0.907
68
15
1.31 Lack of patient need
254
15
1.67 322 6915
0.0026
*Reflects the number of respondents out of 330 total respondents indicating they had not
completed the mandatory training to allow for application for a DEA waiver to prescribe
buprenorphine that provided a response to questions identifying barriers.
Individual ns indicate the number of providers that responded “Yes” to each barrier listed.
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IMPLICATIONS
The study goal was to identify the perceived barriers, willingness, and ability to
treat OUD in WV, and identify potential targets for policy and procedural changes
to support MAT as part of OUD treatment. Only 18% of respondents had
completed the training requirements and received their waiver to prescribe
buprenorphine as part of OUD treatment. More than half of those who did not
currently have a waiver to prescribe buprenorphine indicated a willingness to
complete the requirements if free training and compensation were provided. More
than 80% of waivered providers indicated they had ever prescribed an OUD MAT
drug, higher than the national average of 58%.12 Patient need was identified as
a reason for prescribing MAT in open-ended comments and ranked lowest on
perceived barriers. Results indicate most respondents are currently or are at
least willing to incorporate MAT into their practice to address the opioid epidemic
in WV.
Lack of available mental health or psychosocial support services and drug
misuse/diversion were the two most serious concerns for both waivered and nonwaivered providers, the same top barriers identified in the national study from
which the current survey was adapted6 as well as a similar study of rural primary
care providers5. Forty-eight of WV’s 55 counties are considered Mental Health
Professional Shortage Areas13 and a statewide behavioral health workforce
learning collaborative was established in 2019 to inform policies and practices
addressing this workforce shortage. Work is also underway in WV to expand the
use of telehealth and phone-based apps that can support treatment in rural
areas with few providers and offer more immediate access to services, including
behavioral health. Misuse of diverted buprenorphine is most often done to
manage withdrawal symptoms and avoid risk associated with use of street
drugs.14,15 Training on how to identify withdrawal symptoms and adjust dosing
accordingly may reduce risk of misuse, abuse, and diversion. A 2016 survey of
experienced rural buprenorphine prescribers identified recommendations to
avoid problems with the DEA: all physicians recommended that providers follow
all DEA rules strictly (available on the DEA and SAMHSA websites),16 keep
detailed records, and be prepared for the DEA to visit. Physicians who reported
strictly following these rules did not report being concerned about the DEA.17
It is noteworthy that five of the top six concerns were identical for those providers
who already held the waiver to prescribe buprenorphine and those who had not
yet received the waiver. While there were statistically significant differences
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between their ratings, as well as differences in rank order, most of the concerns
were shared. The very practical concern for financial/payment issues was
ranked fourth by those currently waivered but ranked twelfth for those not
without a waiver.
Results indicated stigma around provision of MAT for treating OUD.
Respondents were more likely to agree reimbursement should be increased for
mental health more generally than for OUD specifically, consistent with previous
studies exploring implicit bias.11 Resistance from practice partners,
administration and community were ranked as minor concerns; however, stigma
was indicated in open-ended comments such as: suboxone is a drug of abuse, I
strongly believe there should be a better way, substitutes one addiction for another
as well as attracting drug users to practice. The latter comment seemed to be a
more serious concern for non-waivered providers.
Medication-assisted treatment expansion efforts are being implemented across
the state and preliminary findings indicate an increased capacity to address the
substance use disorder (SUD)/OUD epidemic, including buprenorphine as part
of treatment.7 WV’s modified hub and spoke model and Project ECHO provide
platforms that can be leveraged to address perceived barriers such as legal
liability, incorporating SUD/OUD treatment into scope of practice, increasing
confidence in patient management, and addressing stigma.
The WV State Substance Use Response Plan goals for 2020–2022 include
increasing the number of providers obtaining waivers by 20% each year, training
current and future health care providers on evidence-based approaches to
treatment and increasing the number of in-state clinical providers to meet needs
of residents seeking SUD treatment.18 Data on perceived barriers from the
current study can inform priorities and activities at state and regional levels to
increase access to SUD treatment.
Limitations include a low response rate and small sample size compared to the
number of potential prescribers in WV, limiting generalizability of findings. Two
percent of the total population targeted by the survey email responded.
Conclusions regarding implicit bias are limited due to the large difference in
number of respondents for each question, potential confounds with question
order, and less stigmatizing language used in the current study (opioid use
disorder) compared to previously published work that used “addiction.”11
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SUMMARY BOX
What is already known on this topic?
Medication-assisted treatment (MAT) is an evidence-based therapy for opioid use
disorder that has not been fully implemented in rural areas due to patient,
provider, and logistical barriers.
What is added by this report?
The current study identified perceived barriers of potential prescribers to use
MAT including buprenorphine as part of treatment for OUD in West Virginia, a
mostly rural state entirely within Appalachia.
What are the implications for future research?
These findings can inform efforts to increase access to SUD treatment in the
Appalachian region by prioritizing, implementing, and evaluating activities that
address providers’ perceived barriers to implementing MAT as part of OUD
treatment.
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